Hugo and coworkers analyzed the transcription features of metastatic melanoma responding or not to anti-PD1 therapy and observed that innately resistant tumors display a transcriptional signature, defined as innate anti-PD-1 resistance (IPRES), showing simultaneous over-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing [175]. The gene discussed is PDCD1; the disease is metastatic melanoma.